ArticleBMC cancer2016

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.

Jean-Pierre Roperch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.